Accuray (ARAY)

ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.

Accuray delivers solid fiscal second-quarter results, witnessing growth in Product revenues and reduced operating expenses.

Accuray Incorporated (NASDAQ:ARAY ) Q2 2025 Results Conference Call February 5, 2025 4:30 PM ET Company Participants Jesse Chew - Chief Legal Officer Suzanne Winter - President and Chief Executive Off...

Although the revenue and EPS for Accuray (ARAY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Stre...

Accuray (ARAY) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.10 per share a year ago.

Accuray (ARAY) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that ma...

Accuray announces the approval of the Chinese NMPA for its latest radiation therapy solutions.

ARAY's solid product demand and revenue growth raise optimism about the stock.

Impressive revenue growth remains elusive for Accuray despite the potential in China, and there are ongoing challenges with profitability, competition, and market scale. The last quarter's results sho...